Video: Every Case Tells a Story| Webinar: ACR/CHEST ILD Guidelines in Practice

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • QA/QI
    • Technology
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

A Practical Guide to Autoantibody Testing in Rheumatic Diseases

Donald Thomas, MD, FACP, FACR, RhMSUS, & Jason Liebowitz, MD  |  Issue: October 2024  |  October 7, 2024

Editor’s Pick: “ANA’s are some of the most commonly ordered tests in rheumatology today, so understanding what they are and why they’re so important is vital for rheumatologists.” —Physician Editor Bharat Kumar, MD, MME, FACP, FAAAAI, RhMSUS

Rheumatic disease labs have advanced since our 2004 article by Dr. Peter Schur (updated in 2009).1-3 However, universally available laboratory advancements are not keeping pace with advancements in rheumatic disease pharmaceutical drugs.4 Diagnosing and managing rheumatic diseases is similar to putting the pieces of a puzzle together. Being the experts in ordering and evaluating the meaning of serologies, such as autoantibodies, complements and other immune system biomarkers, is a fun, challenging part of our profession. It is important to know the strengths and weaknesses of these tests and how they can change one’s pre-test probabilities.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

In this series, we explore the fascinating world of autoantibodies.

Anti-Cell vs. Anti-Nuclear Antibodies

Patients positive for anti-nuclear antibodies (ANA) are among the most common reasons for rheumatology referrals.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

ANAs are antibodies that target any part of the nucleus. However, a positive ANA by indirect immunofluorescence assay (IFA) can also be positive due to autoantibodies targeting extra-nuclear structures, such as in the cytoplasm, or other organelles, such as the mitochondria. Anti-Jo-1 antibody, an anti-synthetase syndrome autoantibody, is one example.

The International Consensus on ANA Patterns proposes using the term anti-cell antibodies instead of ANAs.5 We agree. However, because the term has not been widely adopted, we use ANA throughout this article.

The Expanding Identification

Millions of different autoantibodies can theoretically be directed toward cellular (and extracellular) contents. The list of autoantibodies that play a role in autoimmune diseases continues to grow. More than 200 autoantibodies have been identified to have a role in systemic lupus erythematosus (SLE), more than 60 in systemic sclerosis (SSc) and more than 25 in idiopathic inflammatory myopathies.5

ANAs in Healthy People

Depending upon methodology and the demographic study population, 10–20% of healthy individuals are ANA positive. A positive ANA in a healthy person could be a normal finding or could herald the possibility of an autoimmune disease developing in the future.6 Other possible causes include drugs, genetics and most inflammatory conditions (e.g., infections and cancer).

More than 75 common autoantibodies have been identified in healthy people.7 The most prevalent of these occur in over 25% of healthy individuals. These may occur due to such mechanisms as loss of tolerance and molecular mimicry after infections (e.g., adeno- and herpes viruses).

Page: 1 2 3 4 5 6 | Single Page
Share: 

Filed under:Conditions Tagged with:ANA testautoantibodiesautoantibody testingEditor's Picklaboratory tests

Related Articles

    Laboratory Testing for Diagnosis, Management of Patients with Rheumatic Disease

    December 1, 2014

    A review of data on antinuclear antibodies and tests for rheumatoid arthritis

    Know Your Labs

    February 1, 2009

    A review of state-of-the-art testing for SLE and connective tissue disease.

    Can Lupus Be Prevented? Research Reveals Clues to Who’s Most Likely to Transition to Classified Disease

    February 25, 2020

    How does a patient transition from health to active SLE? This question is the crux of the research conducted by Judith A. James, MD, PhD, and colleagues…

    New Study Reveals Limitations in ANA Test Kits for Lupus

    September 20, 2018

    The variability in serological testing for antinuclear antibodies (ANA) is under investigation after unexpected findings were reported from clinical trials of new agents to treat systemic lupus erythematosus (SLE). In “Assay Variation in the Detection of Antinuclear Antibodies in the Sera of Patients with Established SLE,” David S. Pisetsky, MD, PhD, and his colleagues demonstrate…

  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences